Key result
The TGF-β inhibitor CILP was identified as a novel biomarker for cardiac fibrosis.
Key points are not available for this paper at this time.
[Figure: see text]
No takes yet. Share an insight, caveat, or question.
Groß et al. (2020) studied this question. The TGF-β inhibitor CILP was identified as a novel biomarker for cardiac fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: